Ionis Pharmaceuticals IONS Accrued In Licensing Fees Current
Accrued In Licensing Fees Current at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:AccruedInLicensingFeesCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's accrued in licensing fees current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's accrued in licensing fees current?
- Ionis Pharmaceuticals (IONS) reported accrued in licensing fees current of $6.66M in Q1 2026.
- How has Ionis Pharmaceuticals's accrued in licensing fees current changed year-over-year?
- Ionis Pharmaceuticals's accrued in licensing fees current decreased by 9.8% year-over-year, from $7.37M to $6.66M.
- What is the long-term trend for Ionis Pharmaceuticals's accrued in licensing fees current?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's accrued in licensing fees current has grown at a 1.6% compound annual growth rate (CAGR), from $8.04M to $8.59M.
- What does accrued in licensing fees current mean?
- Short-term debts owed for the use of licensed technology or intellectual property.
- How do you interpret accrued in licensing fees current?
- Increases often correlate with the achievement of development milestones or the expansion of the licensed product portfolio.
- How does accrued in licensing fees current compare across companies?
- Common in companies that rely on external innovation and licensing agreements to supplement internal R&D.